Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


15.06.2020

4 BJU Int
1 Cancer Res
2 Clin Cancer Res
1 Eur J Radiol
7 Eur Urol
2 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 Int J Urol
1 J Clin Oncol
1 J Urol
2 PLoS One
1 Prog Urol
5 Prostate
1 Radiology
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BJU Int

  1. TOMER A, Nieboer D, Roobol MJ, Bjartell A, et al
    Personalized Biopsy Schedules Based on Risk of Gleason Upgrading for Low-Risk Prostate Cancer Active Surveillance Patients.
    BJU Int. 2020 Jun 12. doi: 10.1111/bju.15136.
    PubMed         Abstract available

  2. PFISTER D, Haidl F, Nestler T, Verburg F, et al
    (68) Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer.
    BJU Int. 2020 Jun 12. doi: 10.1111/bju.15135.
    PubMed         Abstract available

  3. FRANKLIN A, Yaxley WJ, Raveenthiran S, Coughlin G, et al
    Histological comparison between predictive value of pre-operative 3T multiparametric MRI and (68) Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
    BJU Int. 2020 Jun 10. doi: 10.1111/bju.15134.
    PubMed         Abstract available

  4. AKAKURA K, Bolton D, Grillo V, Mermod N, et al
    Not All Prostate Cancer is the Same - Patient perceptions: An Asia-Pacific study.
    BJU Int. 2020 Jun 10. doi: 10.1111/bju.15129.
    PubMed         Abstract available


    Cancer Res

  5. XU S, Fan L, Jeon HY, Zhang F, et al
    p300-mediated acetylation of histone demethylase JMJD1A prevents its degradation by ubiquitin ligase STUB1 and enhances its activity in prostate cancer.
    Cancer Res. 2020 Jun 10. pii: 0008-5472.CAN-20-0233.
    PubMed         Abstract available


    Clin Cancer Res

  6. WANG B, Liu C, Wei Y, Meng J, et al
    A prospective trial of (68)Ga-PSMA and (18)F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration.
    Clin Cancer Res. 2020 Jun 11. pii: 1078-0432.CCR-20-0587.
    PubMed         Abstract available

  7. KYRIAKOPOULOS CE, Eickhoff J, Ferrari AC, Schweizer MT, et al
    Multicenter Phase 1 Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer.
    Clin Cancer Res. 2020 Jun 8. pii: 1078-0432.CCR-20-0945.
    PubMed         Abstract available


    Eur J Radiol

  8. MAHJOUB S, Baur ADJ, Lenk J, Lee CH, et al
    Optimizing size thresholds for detection of clinically significant prostate cancer on MRI: Peripheral zone cancers are smaller and more predictable than transition zone tumors.
    Eur J Radiol. 2020;129:109071.
    PubMed         Abstract available


    Eur Urol

  9. BESSA A, Maclennan S, Enting D, Bryan R, et al
    Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Usi
    Eur Urol. 2019 May 17. pii: S0302-2838(19)30379.
    PubMed        

  10. INARRITU JM, Castellani D, Teoh JYC
    Re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol. In press. https://doi.org/10.1016/j.eururo.
    Eur Urol. 2019 May 15. pii: S0302-2838(19)30378.
    PubMed        

  11. LAVORGNA G, Montorsi F, Salonia A
    Re: Hung-Ming Lam, Holly M. Nguyen, Mark P. Labrecque, et al. Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcrip
    Eur Urol. 2020 Jun 8. pii: S0302-2838(20)30363.
    PubMed        

  12. KETTUNEN K, Bostrom PJ, Taimen P
    Reply to Mengxin Lu, Yi Zhang, Yu Xiao's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In
    Eur Urol. 2019 Aug 13. pii: S0302-2838(19)30610.
    PubMed        

  13. ARMSTRONG AJ, Lin P, Tombal B, Saad F, et al
    Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
    Eur Urol. 2020 Jun 9. pii: S0302-2838(20)30329.
    PubMed         Abstract available

  14. SIMPSON BS, Carmona Echeverria LM, Norris JM, Ahmed HU, et al
    Re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol 2020;77:501-7.
    Eur Urol. 2020 Jun 8. pii: S0302-2838(20)30342.
    PubMed        

  15. CHESNUT GT, Vickers AJ, Ehdaie B
    Reply to Benjamin S. Simpson, Lina M. Carmona Echeverria, Joseph M. Norris, Hashim U. Ahmed, Caroline M. Moore, and Hayley C. Whitaker's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnet
    Eur Urol. 2020 Jun 7. pii: S0302-2838(20)30355.
    PubMed        


    Int J Cancer

  16. WENDEU-FOYET MG, Cenee S, Koudou Y, Tretarre B, et al
    Circadian genes polymorphisms, night work and prostate cancer risk: findings from the EPICAP study.
    Int J Cancer. 2020 Jun 7. doi: 10.1002/ijc.33139.
    PubMed         Abstract available

  17. JOCHEMS SHJ, Stattin P, Haggstrom C, Jarvholm B, et al
    Height, body mass index, and prostate cancer risk and mortality by way of detection and cancer risk category.
    Int J Cancer. 2020 Jun 11. doi: 10.1002/ijc.33150.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  18. KOLLMEIER MA, McBride S, Varghese M, Debonis D, et al
    Low dose rate brachytherapy combined with ultra-hypofractionated radiation therapy for clinically localized, intermediate-risk prostate cancer: Results from a prospective trial.
    Int J Radiat Oncol Biol Phys. 2020 Jun 4. pii: S0360-3016(20)31189.
    PubMed        


    Int J Urol

  19. MOMOTA M, Hatakeyama S, Soma O, Tanaka T, et al
    Geriatric 8 screening of frailty in patients with prostate cancer.
    Int J Urol. 2020 Jun 4. doi: 10.1111/iju.14256.
    PubMed         Abstract available


    J Clin Oncol

  20. GIRI VN, Knudsen KE, Kelly WK, Cheng HH, et al
    Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
    J Clin Oncol. 2020 Jun 9:JCO2000046. doi: 10.1200/JCO.20.00046.
    PubMed         Abstract available


    J Urol

  21. LONERGAN PE, Washington SL 3rd, Cowan JE, Zhao S, et al
    Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
    J Urol. 2020 Jun 10:101097JU0000000000001186. doi: 10.1097/JU.0000000000001186.
    PubMed         Abstract available


    PLoS One

  22. CHEN MM, Jahn JL, Barber JR, Han M, et al
    Clinical stage provides useful prognostic information even after pathological stage is known for prostate cancer in the PSA era.
    PLoS One. 2020;15:e0234391.
    PubMed         Abstract available

  23. HUSAINI Y, Tsai VW, Manandhar R, Zhang HP, et al
    Growth differentiation factor-15 slows the growth of murine prostate cancer by stimulating tumor immunity.
    PLoS One. 2020;15:e0233846.
    PubMed         Abstract available


    Prog Urol

  24. ROZET F, Hennequin C, Beuzeboc P, Mathieu R, et al
    [French CCAFU guidelines on prostate cancer: hormone-sensitive metastatic prostate cancer-update 2020].
    Prog Urol. 2020 Jun 6. pii: S1166-7087(20)30139.
    PubMed         Abstract available


    Prostate

  25. TAYLOR RA, Farrelly SG, Clark AK, Watt MJ, et al
    Early intervention exercise training does not delay prostate cancer progression in Pten(-/-) mice.
    Prostate. 2020 Jun 10. doi: 10.1002/pros.24024.
    PubMed         Abstract available

  26. ELHODAKY M, Hong LK, Kadkol S, Diamond AM, et al
    Selenium-binding protein 1 alters energy metabolism in prostate cancer cells.
    Prostate. 2020 Jun 8. doi: 10.1002/pros.24028.
    PubMed         Abstract available

  27. CHADID S, Barber JR, Nelson WG, Gurel B, et al
    The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial.
    Prostate. 2020 Jun 7. doi: 10.1002/pros.24023.
    PubMed         Abstract available

  28. CARSON JJK, Di Lena MA, Berman DM, Siemens DR, et al
    Development and initial clinical correlation of a DNA methylation-based blood test for prostate cancer.
    Prostate. 2020 Jun 7. doi: 10.1002/pros.24025.
    PubMed         Abstract available

  29. RII J, Sakamoto S, Yamada Y, Takeshita N, et al
    Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
    Prostate. 2020 Jun 5. doi: 10.1002/pros.24016.
    PubMed         Abstract available


    Radiology

  30. ZHANG Z, Wu HH, Priester A, Magyar C, et al
    Prostate Microstructure in Prostate Cancer Using 3-T MRI with Diffusion-Relaxation Correlation Spectrum Imaging: Validation with Whole-Mount Digital Histopathology.
    Radiology. 2020 Jun 9:192330. doi: 10.1148/radiol.2020192330.
    PubMed         Abstract available


    Urology

  31. KAUFMAN ME, Miller DT, Ullah A, White J, et al
    Skene's Gland Adenocarcinoma: Borrowing from Prostate Cancer Experience for the Evaluation and Management of a Rare Malignancy.
    Urology. 2020 Jun 3. pii: S0090-4295(20)30632.
    PubMed         Abstract available

  32. CULLEN J, Kuo HC, Shan J, Lu R, et al
    The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate Cancer.
    Urology. 2020 Jun 7. pii: S0090-4295(20)30623.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: